mProX™ Human ACE2 Stable Cell Line

Product Information

Target Family

Virology

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;MDA-MB-231;MCF-7

Target Classification

Virology Cell Lines

Target Research Area

Immunology Research

Related Diseases

Covid-19; Hartnup Disorder

Gene ID

Human:59272

UniProt ID

Human:Q9BYF1

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

ACE2 (angiotensin-converting enzyme 2) has several applications related to SARS-CoV-2. In one study, computational techniques were used to design neutralizing Nbs that can effectively neutralize the receptor-binding domain (RBD) of SARS-CoV-2 variants of concern (VOCs). These engineered Nbs have the potential to be used in RBD-neutralizing assays, aiding in the development of novel treatment, prevention, and diagnostic strategies against SARS-CoV-2. Another study highlighted the role of ACE2-mediated NF-Œ∫B activation in COVID-19 patients and the potential use of NF-Œ∫B activation inhibitors for favorable prognosis. Additionally, ACE2 expression was found to be lower in the respiratory tract of dogs compared to cats, which may contribute to differences in susceptibility to SARS-CoV-2 infection between these species. Finally, ACE2-derived peptides were synthesized and evaluated for their potential to inhibit SARS-CoV-2 cell entry, showing promising results against different variants of the virus. These findings suggest that ACE2 and its derivatives have potential applications in therapeutic and diagnostic strategies against SARS-CoV-2.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human ACE2 Stable Cell Line (S01YF-1023-PY163). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Jordan Garcia (Verified Customer)

How does ACE2 interaction with SARS-CoV-2 affect cell entry? Jul 07 2023

chat Patrick Liam (Creative Biolabs Scientific Support)

ACE2 acts as a receptor for the SARS-CoV-2 virus, facilitating its entry into cells. The spike protein of the virus binds to ACE2, initiating the process of viral entry and infection. Jul 07 2023

chat Alex Davis (Verified Customer)

Is there a risk associated with ACE2 expression in hypertension patients regarding COVID-19? Apr 07 2022

chat Patrick Liam (Creative Biolabs Scientific Support)

Hypertension patients may have an increased expression of ACE2, which could elevate the risk of developing COVID-19 due to the enhanced potential for the virus to bind and enter cells. Apr 07 2022

Published Data

Fig.1 ACE2 suppresses the migratory capabilities of breast cancer cells.

The study examined the differential protein expressions of ACE2 in two distinct breast cancer cell lines, specifically MDA-MB-231 cells overexpressing ACE2 and ACE2-knockdown MCF-7 cells. To evaluate the impact of ACE2 on cell behavior, a Transwell migration assay was conducted on these genetically manipulated MDA-MB-231 and MCF-7 cells, aiming to understand how ACE2 modulation influences their migratory abilities.

Ref: Zhang, Qi, et al. "ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa/VEGFR2/ERK pathway." Journal of Experimental & Clinical Cancer Research 38.1 (2019): 1-12.

Pubmed: 31023337

DOI: 10.1186/s13046-019-1156-5

Research Highlights

Sánchez-Morales, Lidia, et al. "A retrospective study of SARS-CoV-2 seroprevalence in dogs and cats in the Community of Madrid, Spain." Frontiers in Microbiology 14 (2023): 1264172.
Several studies have been conducted to investigate the susceptibility of domestic animals, specifically cats and dogs, to SARS-CoV-2 infection. However, there is a need for vigilant monitoring of these animals to track any potential changes in the course of the disease in these species. A retrospective study was conducted to analyze stored sera samples (collected between 2018-2020) from domestic cats and dogs for the presence of SARS-CoV-2 antibodies. This study aims to gain further insight into the potential infection and spread of the virus in domestic animals.
Sánchez-Morales, Lidia, et al. "A retrospective study of SARS-CoV-2 seroprevalence in dogs and cats in the Community of Madrid, Spain." Frontiers in Microbiology 14 (2023): 1264172.
Pubmed: 37869682 DOI: 10.3389/fmicb.2023.1264172

Boshah, Hattan. et al. "Evaluation of Potential Peptide-Based Inhibitors against SARS-CoV-2 and Variants of Concern." BioMed research international, 2023.
The global impact of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has been significant. Despite the development of vaccines and pharmaceutical treatments, concerns have arisen due to the emergence of various mutated variants. Despite mutations in these variants, the angiotensin-converting enzyme (ACE2) receptor remains the key mechanism for the virus to enter cells. As a potential therapeutic strategy, targeting and inhibiting the spike protein of the virus, which identifies and binds to the ACE2 receptor, has been proposed. In this study, two ACE2-derived peptides, P1 and P25, were synthesized and evaluated as potential inhibitors for SARS-CoV-2 cell entry.
Boshah, Hattan. et al. "Evaluation of Potential Peptide-Based Inhibitors against SARS-CoV-2 and Variants of Concern." BioMed research international, 2023.
Pubmed: 37869628 DOI: 10.1155/2023/3892370